KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to -$77.2 million.

  • Vertex Pharmaceuticals' Cash from Financing Activities rose 8027.09% to -$77.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.3 billion, marking a year-over-year decrease of 5126.76%. This contributed to the annual value of -$2.3 billion for FY2025, which is 5126.76% down from last year.
  • Vertex Pharmaceuticals' Cash from Financing Activities amounted to -$77.2 million in Q4 2025, which was up 8027.09% from -$1.2 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $47.7 million during Q2 2022, with a 5-year trough of -$1.2 billion in Q3 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$315.4 million (2021), whereas its average is -$293.2 million.
  • In the last 5 years, Vertex Pharmaceuticals' Cash from Financing Activities soared by 11195.72% in 2022 and then plummeted by 217283.24% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$336.2 million in 2021, then skyrocketed by 111.96% to $40.2 million in 2022, then tumbled by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then skyrocketed by 80.27% to -$77.2 million in 2025.
  • Its Cash from Financing Activities was -$77.2 million in Q4 2025, compared to -$1.2 billion in Q3 2025 and -$349.2 million in Q2 2025.